Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
PARTHENOPE Trial: A New Benchmark in Risk Score Validation
Davide Capodanno/X
Sep 4, 2025, 11:52

PARTHENOPE Trial: A New Benchmark in Risk Score Validation

Davide Capodanno, Professor of Cardiology at the University of Catania, editor-in-Chief of EuroIntervention, posted on X:

”I think I have a positive bias toward the PARTHENOPE trial, not only because I was part of the Steering Committee and deeply respect the work behind it, but also because it does something rarely done when validating risk scores: randomization. Usually, we see validation based on discrimination or area under the curve, but in reality, the true test of a score’s utility is whether randomization to a score-guided versus non–score-guided strategy makes a difference on clinical outcomes. Just think of how many scores we use every day that lack this kind of validation.”

Read more here.

PARTHENOPE

Stay updated with Hemostasis Today.

bleeding disorders Davide Capodanno Health Hematology Hemophilia Hemostasis Hemostasis Today Medicine PARTHENOPE randomization thrombosis
NewsFeed